Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using a patient driven approach, we are working to discover and develop innovative medicines to safely and effectively treat disease and improve patient lives.
Through our Genome5000™ program, Lexicon scientists spent more than a decade studying the role and function of nearly 5,000 genes to pinpoint the key targets for drug development. This systematic, targeted approach led us to identify more than 100 protein targets with significant therapeutic potential in a wide range of diseases. These precise targets serve as our roadmap for the development of pioneering medicines that have the potential to improve the standard of care for patients so that they can live better, more empowered lives.
Our passion is to bring medicines to the market that have the potential to improve the standard of care for diseases that have not experienced new treatment innovation in years – decades, in some cases. We are not driven by any particular disease area or patient population. Rather, using our roadmap of precise targets, we intentionally seek out relatively unexplored mechanisms. Our approach may not be the easiest path, but we believe that, in the long-term, it will ultimately provide the greatest benefit to patients.
We believe in treating people, not just diseases. Our focus is patient driven and we are committed to listening, assisting and working with patient communities to best serve the patient. Our goal is to generate truly impactful solutions for patients that will make meaningful, long-term improvements in their lives.